Sanofi has posted the full results from the EDITION II study showing that its investigational new insulin, U300, demonstrated similar blood sugar control with 23% fewer patients experiencing night-time low blood sugar compared with Lantus (insulin glargine [rDNA origin] injection). The results were presented at the International Diabetes Federation 2013 World Diabetes Congress in Melbourne, Australia. The full EDITION II results are consistent with those from EDITION I. Both studies were conduc...